IN BRIEF: IXICO will see 2022 revenue drop after contract canceled

IXICO PLC - London-based neuroscience data analytics company - Says 2022 revenue will decrease by ...

Alliance News 20 January, 2022 | 2:35PM
Email Form Facebook Twitter LinkedIn RSS

IXICO PLC - London-based neuroscience data analytics company - Says 2022 revenue will decrease by GBP300,000 after Huntington's disease study contract canceled by client. The study had been using IXICO's safety and data analysis service to support the understanding of findings, in an open-label extension after phase three trials ended. The contract was due to run for three more years. The company's order book now totals GBP12.6 million, including the loss from the cancellation.

IXICO says it has a "strong pipeline of opportunities" with the client, who is designing a new phase two clinical trial for the investigative drug for the treatment of Huntingdon's disease.

Current stock price: 52.54 pence, down 9.4% on Thursday

12-month change: down 41%

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
IXICO PLC 8.75 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures